Market Research Report
Market Spotlight: Uterine Cancer
|Published by||Datamonitor Healthcare||Product code||603896|
|Published||Content info||45 Pages
Delivery time: 1-2 business days
|Market Spotlight: Uterine Cancer|
|Published: December 4, 2019||Content info: 45 Pages||
This Market Spotlight report covers the uterine cancer market, comprising key pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, recent events and analyst opinion, key upcoming events, probability of success, and licensing and acquisition deals.
Datamonitor Healthcare estimates that in 2017, there were 377,900 incident cases of uterine cancer in females aged 15 years and over worldwide, and expects that number to increase to 413,600 incident cases by
2026. In the same year, there were an estimated 1.3 million five-year prevalent cases of uterine cancer worldwide, which is expected to increase slightly to 1.4 million cases by
2026. Merck's Keytruda and Eisai's Lenvima are the only FDA-approved drugs for uterine cancer. These drugs are administered via the intravenous and oral routes.
The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II, with two drugs in Phase III.
Therapies in active clinical development for uterine cancer focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.
The only high-impact upcoming event in the uterine cancer space is the release of topline Phase II trial results for XBIO-101. The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 41%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
There have been nine licensing and asset acquisition deals involving endometrial cancer drugs during 2014-19. The $1,657m collaboration and exclusive license agreement signed in 2014 between AnaptysBio and Tesaro, pursuant to which Tesaro was granted exclusive rights to antibody programs targeting PD-1, TIM-3, and LAG-3, including monospecific and dual reactive antibody drug candidates, was the largest deal.
The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for uterine neoplasms have been in the early and mid-phases of development, with 94% of trials in Phase I-II, and only 6% in Phase III-IV.
The US has a substantial lead in the number of uterine neoplasms clinical trials globally, while Spain and the UK lead the major EU markets.
Sanofi has the highest number of completed clinical trials for uterine neoplasms, with five trials.
AstraZeneca leads the industry sponsors with the highest number of overall clinical trials for uterine neoplasms
9 Radiation therapy
10 Hormone therapy
10 Palliative care
24 MGA012 for Uterine Cancer (July 2, 2019)
25 Sacituzumab Govitecan for Uterine Cancer (April 29, 2019)
25 TAK-117 for Uterine Cancer (March 20, 2019)
26 Dostarlimab for Uterine Cancer (March 19, 2019)
28 DKN-01 for Uterine Cancer (March 18, 2019)
29 Dostarlimab for Uterine Cancer (October 20, 2018)
31 Keytruda for Uterine Cancer (June 3, 2018)
34 FDA Issues Pair Of RTOR Approvals To Keytruda/Lenvima Combo, Erleada
34 Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer
36 Deals Shaping The Medical Industry, August 2019
40 Sponsors by status
41 Sponsors by phase
43 Prescription Information